Can-Fite BioPharma Ltd.
Reinhold Cohn House
317 articles with Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. announced the agreement by several accredited investors to exercise certain warrants to purchase up to an aggregate of 22,278,540 ordinary shares represented by 742,618 American Depositary Shares having exercise prices ranging from $12.90 to $78.75 per ADS issued by Can-Fite in September 2015, October 2015, March 2018, January 2019 and April 2019, at a reduced exercise price of $3.25 per ADSs.
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, issued a Letter to Shareholders from the Company’s Chief Executive Officer, Pnina Fishman, Ph.D.
Psoriasis therapeutic market estimated to reach $11.4B in 2020
Can-Fite to Attend BioFIT 2019 Conference in Europe with Focus on Partnering Meetings for Namodenoson in NASH
Topline results from NASH Phase II study expected Q1 2020
Reached agreement with U.S. FDA on Phase III liver cancer study design & initiated compassionate use program in Israel
Can-Fite BioPharma Ltd. (NYSE American: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced its CEO Pnina Fishman Ph.D. will share insight into the Company’s recent developments during an investor webinar on Monday, November 25, 2019
Can-Fite Granted U.S. Patent for Piclidenoson in the Treatment of Osteoarthritis, Positioning this Indication for Animal Health Market
Treatment of arthritis in canines is an estimated $1.9 billion annual market with unmet need for safe and effective oral drug
Can-Fite Initiates Compassionate Use Program for Namodenoson in the Treatment of Liver Cancer, Enrolls and Treats Patients
Based on encouraging Phase II results, patients with underlying CPB7 cirrhosis who lack a viable treatment option are now provided Namodenoson
U.S. FDA Agreed with Can-Fite’s Proposed Pivotal Phase III Trial Design to Support a New Drug Application Submission and Approval of Namodenoson in the Treatment of Liver Cancer
Successful conclusion of an End of Phase II meeting with the FDA
Can-Fite BioPharma Ltd. announced an interview with CEO Pnina Fishman Ph.D. will air on The RedChip Money Report television program.
Can-Fite BioPharma Ltd. announced it has completed patient enrollment in its Phase II study of Namodenoson in the treatment of NAFLD/NASH.
Can Fite Announces Publication of Namodenoson™ NASH Mechanism of Action in International Journal of Molecular Medicine
In pre-clinical studies Namodenoson™ significantly reduced liver inflammation and fibrosis via de-regulation of the Wnt and the NF-kB mechanistic pathway
Can-Fite Presents New Data on the Treatment of Advanced Liver Cancer with Namodenoson at the ILCA Conference
International Liver Cancer Association (ILCA) is devoted exclusively to liver cancer research
Can-Fite Enters into Strategic Agreement with Univo Pharmaceuticals to Develop Cannabinoid-Based Pharmaceuticals and Assays
Can-Fite BioPharma Ltd. announced it has entered into a collaboration agreement with Univo Pharmaceuticals, a medical cannabis company, to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases.
Can-Fite to Present at H. C. Wainwright 21st Annual Global Investment Conference on September 10, 2019
Can-Fite BioPharma Ltd. announced the Company’s CEO Dr. Pnina Fishman will present at the H. C. Wainwright 21st Annual Global Investment Conference to be held on September 8-10, 2019 at the Lotte New York Palace Hotel in New York City.
Can-Fite BioPharma Ltd. announced financial results for the six months ended June 30, 2019.
Can-Fite to Treat Advanced Liver Cancer Patients with Namodenoson Under Compassionate Use Setting in Israel
Drug supply for compassionate use has been manufactured and is ready for use
Can-Fite Signs Agreement with Kyongbo Pharm for the Distribution in South Korea of Piclidenoson in the Treatment of Psoriasis
Up to $4,000,000 in upfront and milestone payments, plus a transfer price for delivering finished product
Can-Fite Participating in One-on-One Partnering Meetings at the BIO International Convention on June 3-6, 2019
Can-Fite BioPharma Ltd. announced that the Company’s VP of Business Development, Sari Fishman, is conducting one-on-one meetings with pharmaceutical companies for potential distribution and partnerships for the Company’s drug candidates, Piclidenoson and Namodenoson, at the BIO International Convention 2019 on June 3-6, 2019 in Philadelphia.
Findings from Can-Fite’s Phase II Liver Cancer Study were Presented at ASCO Annual Meeting Late-Breaking Session
Phase III study protocol for Namodenoson in the treatment of advanced liver cancer patients is now being prepared and will be presented to FDA in an End of Phase II meeting